The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs

Bone Marrow Transplantation

Volumn 50, Issue 6, 2015, Pages 822-828

  Franssen, L E ^a,b   Van De Donk, N W C J ^b   Emmelot, M E ^a,b   Roeven, M W H ^c   Schaap, N ^c   Dolstra, H ^c   Hobo, W ^c   Lokhorst, H M ^b   Mutis, T ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; LENALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD14+ MYELOID DERIVED SUPPRESSOR CELL; CD14- MYELOID DERIVED SUPPRESSOR CELL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; SUPPRESSOR CELL; TREATMENT OUTCOME; TREATMENT RESPONSE; ALLOGRAFT; BONE MARROW CELL; CLINICAL TRIAL; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; STEM CELL TRANSPLANTATION;

ADULT; AGED; ALLOGRAFTS; FEMALE; GRAFT VS TUMOR EFFECT; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOID CELLS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY;

EID: 84930374809     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.48     Document Type: Article

References (37)

1. Lokhorst HM, Segeren CM, Verdonck LF, Van Der Holt B, Raymakers R, van Oers MHJ, et al. Partially T-cell-depleted allogeneic stem-cell transplantation for firstline treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 2003; 21: 1728-1733
2. Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179-1184
3. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NWCJ, van Oers MHJ, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362-4364
4. Van de Donk NWCJ, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006; 37: 1135-1141
5. Zeiser R, Finke J. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versusmyeloma effect. Eur J Cancer 2006; 42: 1601-1611
6. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-268
7. Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, et al. Recipient-type specific CD4+CD25+regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003; 112: 1688-1696
8. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150
9. Taylor P a. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499
10. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921-3928
11. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061-1070
12. Trzonkowski P, Bieniaszewska M, Juscinska J, Dobyszuk A, Krzystyniak A, Marek N, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells. Clin Immunol 2009; 133: 22-26
13. Guichelaar T, Emmelot ME, Rozemuller H, Martini B, Groen RWJ, Storm G, et al. Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells. Clin Cancer Res 2013; 19: 1467-1475
14. Xia G, Truitt RL, Johnson BD. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 2006; 12: 397-407
15. Nadal E, Garin M, Kaeda J, Apperley J, Lechler R, Dazzi F. Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2007; 21: 472-479
16. Hicheri Y, Bouchekioua A, Hamel Y, He J, Pautas C, Beaumont J, et al. Donor regulatory T cells identified by FoxP3 expression phenotype influence graftversus-tumor effect after donor lymphocyte infusion. J Immunother 2008; 31: 806-811
17. Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cheraï M, et al. CD4 +CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2010; 2: 41ra52
18. Luyckx a, Schouppe E, Rutgeerts O, Lenaerts C, Koks C, Fevery S, et al. Subset characterization of myeloid-derived suppressor cells arising during induction of BM chimerism in mice. Bone Marrow Transplant 2012; 47: 985-992
19. Wang D, Yu Y, Haarberg K, Fu J, Kaosaard K, Nagaraj S, et al. Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice. Biol Blood Marrow Transplant 2013; 19: 692-702
20. Highfill SL, Rodriguez PC, Zhou Q, Goetz C a, Koehn BH, Veenstra R, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010; 116: 5738-5747
21. Mougiakakos D, Jitschin R, von Bahr L, Poschke I, Gary R, Sundberg B, et al. Immunosuppressive CD14+HLA - DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia 2013; 27: 377-388
22. Görgün GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013; 121: 2975-2987
23. Brimnes MK, Vangsted a J, Knudsen LM, Gimsing P, Gang a O, Johnsen HE, et al. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR-/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010; 72: 540-547
24. Ramachandran IR, Martner A, Pisklakova A, Condamine T, Chase T, Vogl T, et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol 2013; 190: 3815-3823
25. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693-1700
26. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701-1711
27. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757
28. Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473
29. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217
30. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty PHows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828
31. Mutis T, Aarts-Riemens T, Verdonck LF. The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions. Haematologica 2005; 90: 1389-1395
32. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291-1297
33. Giannopoulos K, Kaminska W, Hus I, Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer 2012; 106: 546-552
34. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 2012; 61: 353-362
35. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-648
36. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 2012; 72: 3439-3444
37. Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011; 19: 1737-1746